Biopharmaceutical company MapLight Therapeutics (MPLT.US) applies for U.S. stock IPO with plans to raise up to $100 million.

According to the Zhtng Cijng app, the biotechnology company MapLight Therapeutics (MPLT.US), which focuses on the development of therapies for neurological and mental illnesses as well as central nervous system (CNS) diseases, in the clinical phase 2 stage, submitted an application to the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to $100 million through an initial public offering (IPO).